Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35973369/
Acute lung injury (ALI) is a disease characterized by pulmonary diffusion dysfunction and its exacerbation stage is acute respiratory distress syndrome (ARDS), which may develop to multiple organ failure and...
Conclusion: In summary, ZB has shown therapeutic effect in LPS-induced acute lung injury in mice, which provides a potential candidate drug to treat acute lung injury.
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35966045/
1 Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2 Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd.,...
Conclusion/Relevance: The choice of BTK inhibitor is largely patient-specific, and this review aims to highlight the differences among the agents and guide the choice of BTK inhibitor in clinical practice.
Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia
Source : https://www.tandfonline.com/doi/abs/10.1080/14656566.2022.2113384?journalCode=ieop20
Abstract The Bruton's tyrosine kinase (BTK) pathway has proven to be an effective and transformative therapeutic target in the treatment of chronic lymphocytic leukemia (CLL), fueling the growth of BTK...
Expert opinion: BTKis have signaled the start of a new treatment paradigm in CLL and improved clinical outcomes especially for patients with high-risk disease. However, drug resistance, low CR rates, and indefinite treatment necessitate the development of novel BTKis and fixed duration combination therapy. The results from recently completed...
Ibrutinib combined with low-dose HDAC inhibitor chidamide synergistically enhances the anti-tumor effect in B-cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35975476/
Aberrant activity of histone deacetylases (HDACs) is frequently detected in B-cell lymphomas, which indicated the therapeutic implications of HDAC inhibitors for B-cell malignancies. We have discovered that lymphoma cells treated...
Relevance: Our study intended to explore whether the addition of ibrutinib (BTK inhibitor) to chidamide (HDAC inhibitor) could generate combined anti-tumor effects in B-cell lymphomas.
Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review
Source : https://www.frontiersin.org/articles/10.3389/fonc.2022.941633/full
Zanubrutinib, a next-generation non-covalent Bruton's tyrosine kinase (BTK) inhibitor, shows great efficacy in the treatment of B cell malignancies. Some patients may experience a series of side effects after the...
Conclusion: The majority of patients can be relieved with symptomatic treatment, but a very small percentage of patients may face discontinuation of the drug.
-
Leukemia and Lymphoma Connect3yrKey Points • Source: Frontiers in Oncology • Relevance: “Here, we retrospectively reported three cases of dermatological toxicities induced by zanubrutinib. All three patients developed grade 4 skin adverse effects, which lead to a Show More